Nearly 90 billion yuan of financing in the field of medical and health care antibody drugs are integrated into one body: the amount of financing exceeds the sum of four years

The change of policy affects the development of medical and health market, and also directly affects the investment and financing in this field With healthy China becoming a national strategy, capital has also poured into this area Alibaba, Tencent, Baidu, Jingdong, as well as biomedical listed companies, industrial funds and many cross-border capital have entered this field Medical e-commerce, intelligent medicine, Internet hospital, innovative medicine, etc., have become hot investment However, there is a high threshold for investment in health care As time goes on, capital tends to be rational On November 7, the whale Research Institute released the 2018 China Medical and health industry report According to the data, from the perspective of the overall investment and financing situation, the financing amount of the medical industry continues to rise In 2014, the total domestic financing amount of the medical industry was 27.8 billion yuan, and the total financing amount in the first three quarters of 2018 has reached 89.1 billion yuan Drugs and medical services are the two fastest growing sectors, reaching 44.7 billion yuan and 24.8 billion yuan respectively in the first three quarters of 2018 However, there is a downward trend in the number of financing events The data shows that after 2014, the financing heat gradually increased, and by 2016 and 2017, the financing events were basically the same In 2018, the events began to decline, and the total number of investment events in the first three quarters was 716 In addition, the industry financing tends to a single high-end financing and angel round financing sharply reduced Meanwhile, the proportion of intra industry M & A and strategic investment increased from 1.7% and 4.7% in 2014 to 12.4% and 9.2% in 2018, respectively According to Jingzhun Research Institute, this phenomenon reflects that the medical industry is becoming mature, early projects are gradually reduced, investment is more concentrated in the head office, and the importance of M & A and strategic investment is gradually increasing In terms of financing hot areas, antibody drugs, online consultation and medical e-commerce are the hottest areas in the first three quarters of 2018 Among them, the antibody drug financing performance is brilliant, which can be said to be a collection of glory and favor Data shows that from January 2014 to September 2018, 79 financing events occurred in the domestic antibody drug industry, with a financing amount of 19.09 billion yuan Financing events and financing amount are increasing year by year: in terms of the number of financing events, the number of financing events has gradually increased since 2014, with only 6 antibody financing events in 2014 and 24 in 2018; in terms of capital amount, the financing amount of antibody field in 2018 is 9.93 billion yuan, which is more than the sum of the previous four years In the current cold situation of the capital market as a whole, the enthusiasm of antibody drug industry continues to rise Behind this data is the acceleration of financing by innovative pharmaceutical companies in Hong Kong Since August this year, including Geli pharmaceutical, Baiji Shenzhou, Hualing pharmaceutical, and Xinda biology have been listed in Hong Kong In addition, innovative pharmaceutical companies such as Junshi biology have also joined the IPO force in Hong Kong Among them, Baiji Shenzhou, Xinda biology and Junshi biology are regarded as the first echelon representatives of PD-1 drugs in China Jingzhun Research Institute believes that with the introduction of new listing regulations by the Hong Kong stock exchange, allowing biotechnology companies without earnings or profits to be listed in Hong Kong, more and more venture capital will enter the field of new drug research and development in the future, and the investment enthusiasm of antibody drug market will continue to rise With the expiration of the patent for the original research blockbuster in the future, domestic bio analogues can obtain some market shares by virtue of their price advantages, and at the same time drive the price of antibody drugs down, so that more patients can benefit But at the same time, we must be alert to the overheating of the hot target market.